CELL INTELLIGENCE · 肿瘤细胞治疗研究

桥接反应对大 B 细胞淋巴瘤 CD19 CAR-T 细胞治疗后结局的影响

Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

一例复发 ALL 儿童患者 CAR-T 细胞治疗后重度细胞因子释放综合征

Severe Cytokine Release Syndrome After CAR T Cell Therapy in a Pediatric Patient With Relapsed ALL.

本病例凸显了难治性儿童 CRS 的实用床旁序贯治疗与升级，并提示在一线治疗不充分时持续静脉注射 anakinra 和 emapalumab 可能具有潜在作用。

新型合并症指数与大 B 细胞淋巴瘤 CAR-T 细胞治疗后的生存相关

New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

大 B 细胞淋巴瘤的本地生产与商业化 CAR-T 治疗：一项多中心倾向性评分匹配分析

Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma: a multicenter propensity scorematched analysis.

当 BiTE 还坐在儿童桌，CAR 在儿童 B-ALL 中如何切入？

With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?

大 B 细胞淋巴瘤中 CD19 CAR-T 细胞治疗反应的预测因素：一项整合综述

Predictors of response to CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a consolidated review.

SOHO 前沿进展与待解问题｜老年弥漫大 B 细胞淋巴瘤：综合综述

SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review.

嵌合抗原受体（CAR）T 细胞方案治疗原发性骨肿瘤的疗效与适用性：现有证据的综合综述

The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evi

复发/难治性 B 细胞非霍奇金淋巴瘤抗 CD19 CAR-T 细胞治疗后的迟发事件

Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

CAR-T19 与临床意义显著的长期效应相关，如持续性血细胞减少、低丙种球蛋白血症和感染，需要临床监测，但大多可控，非复发死亡风险低。

大 B 细胞淋巴瘤 CAR-T 细胞治疗后的异基因造血细胞移植

Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma.